Comparable stake leader
JOHNSON & JOHNSON
SEC ownership of CVRx, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001235912.
Disclosed value leader
JOHNSON & JOHNSON
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- CVRX on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
JOHNSON & JOHNSON
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
JOHNSON & JOHNSON
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001235912
- Issuer location
- Minneapolis, MN
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CVRx, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
JOHNSON & JOHNSON
Disclosed value leader
JOHNSON & JOHNSON
Comparable rows
50/50
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 15%
13D/G row: JOHNSON & JOHNSON
Showing 1-8 of 50 holder rows.
Quick read
JOHNSON & JOHNSON leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens JOHNSON & JOHNSON's linked filing trail.
Comparable ownership
Top 5
JOHNSON & JOHNSON
15%
NEW ENTERPRISE ASSOCIATES 10 L P
7.8%
Vensana Capital I GP, LLC
7.2%
Gilde Healthcare IV U.a. Cooperat...
4.9%
NEA Management Company, LLC
7.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| JOHNSON & JOHNSON |
3/4/5
13D/G
13F
10%+ Owner · Company
|
15%
from 13D/G
|
$40,369,355
4,024,861 shares
|
-$861,042 | 26 Nov 2025 |
| NEW ENTERPRISE ASSOCIATES 10 L P |
3/4/5
13D/G
10%+ Owner · New Enterprise Associates 10, Limited Partnership
|
7.8%
from 13D/G
|
$37,593,767
2,026,083 shares
|
— | 02 Jul 2021 |
| Vensana Capital I GP, LLC |
13D/G
Kirk Nielsen
|
7.2%
|
$11,849,740
1,760,734 shares
|
$0 | 31 Dec 2024 |
| Gilde Healthcare IV U.a. Cooperatieve |
13D/G
Cooperatieve Gilde Healthcare IV U.A.
|
4.9%
|
$8,287,928
1,231,490 shares
|
$0 | 04 Feb 2025 |
| NEA Management Company, LLC |
13F
Company
|
7.8%
|
$19,166,745
2,026,083 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
3.9%
|
$9,711,248
1,026,559 shares
|
— | 31 Mar 2026 |
| GSK plc |
3/4/5
13F
10%+ Owner · Company
|
3.9%
from 13F
|
$18,695,602
1,007,583 shares
|
— | 02 Jul 2021 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.5%
|
$8,620,993
911,310 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$687,240.
Buys
$300,377
Insiders: 1
Sells
$987,617
Insiders: 6
Net
-$687,240
Shares: -53,523
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 47,400
Shares: 100,923
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 47,400 | 16,017 | $300,377 | $126,575 | +$173,802 |
| 6-9 | 0 | 84,906 | $0 | $861,042 | -$861,042 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 27 reporting-owner rows connected to CVRx, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
27
Largest Forms 3/4/5 holder
Johnson & Johnson Innovation - JJDC, Inc.
Net 12M change
-$687,240
Latest report
01 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 10%+ Owner | $64,860,045 | Mixed | 15 Sep 2023 | ||
| JOHNSON & JOHNSON | 10%+ Owner | $40,369,355 | -$861,042 | -2.1% | Filing P/S | 26 Nov 2025 |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10%+ Owner | $37,593,767 | Mixed | 02 Jul 2021 | ||
| Geoffrey B. Pardo | Director | $33,990,694 | Mixed | 02 Jul 2021 | ||
| GSK plc | 10%+ Owner | $18,695,602 | Mixed | 02 Jul 2021 | ||
| Kirk G. Nielsen | Director | $18,292,450 | Mixed | 01 Jun 2026 | ||
| Mudit K. Jain | Director | $9,548,563 | +$300,377 | +3.2% | Mixed | 01 Jun 2026 |
| NEA PARTNERS 10 L P | 10%+ Owner | $3,217,197 | Mixed | 02 Jul 2021 | ||
| Kevin Hykes | PRES & CEO, Director | $3,007,107 | -$61,349 | -2% | Mixed | 27 Feb 2026 |
| Jared Oasheim | Chief Financial Officer | $933,819 | -$13,781 | -1.5% | Mixed | 27 Feb 2026 |
| Robert Allen John | Chief Revenue Officer | $875,257 | -$31,326 | -3.5% | Mixed | 27 Feb 2026 |
| Philip B. Adamson | Chief Medical Officer | $640,862 | -$9,973 | -1.5% | Mixed | 27 Feb 2026 |
| Paul Verrastro | Chief Mktg & Strat Officer | $601,864 | -$10,146 | -1.7% | Mixed | 27 Feb 2026 |
| Nadim Yared | CHIEF EXECUTIVE OFFICER, Director | $600,518 | Mixed | 02 Feb 2024 | ||
| John Brintnall | Chief Strategy Officer And Sec | $584,980 | Mixed | 22 Apr 2022 | ||
| Joseph P. Slattery | Director | $512,484 | Mixed | 01 Jun 2026 | ||
| Michael D. Dale | Director | $274,387 | Median | 01 Jun 2026 | ||
| Kevin J. Ballinger | Director | $268,266 | Mixed | 01 Jun 2026 | ||
| Mitch C. Hill | Director | $268,266 | Mixed | 01 Jun 2026 | ||
| Martha Shadan | Director | $222,583 | Mixed | 01 Jun 2026 |
Recent insider transactions for CVRx, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kirk G. Nielsen | CVRX | Common Stock | Award | 8,720 | 8,720 | 01 Jun 2026 | Direct | |||
| Kirk G. Nielsen | CVRX | Stock Option (right to buy) | Award | 11,182 | 11,182 | 01 Jun 2026 | Direct | |||
| Mudit K. Jain | CVRX | Common Stock | Award | 154.3% | 8,720 | 14,370 | 01 Jun 2026 | Direct | ||
| Mudit K. Jain | CVRX | Stock Option (right to buy) | Award | 11,182 | 11,182 | 01 Jun 2026 | Direct | |||
| Joseph P. Slattery | CVRX | Common Stock | Award | 28.4% | 8,720 | 39,365 | 01 Jun 2026 | Direct | ||
| Joseph P. Slattery | CVRX | Stock Option (right to buy) | Award | 11,182 | 11,182 | 01 Jun 2026 | Direct | |||
| Mitch C. Hill | CVRX | Common Stock | Award | 8,720 | 8,720 | 01 Jun 2026 | Direct | |||
| Mitch C. Hill | CVRX | Stock Option (right to buy) | Award | 11,182 | 11,182 | 01 Jun 2026 | Direct | |||
| Kevin J. Ballinger | CVRX | Common Stock | Award | 8,720 | 8,720 | 01 Jun 2026 | Direct | |||
| Kevin J. Ballinger | CVRX | Stock Option (right to buy) | Award | 11,182 | 11,182 | 01 Jun 2026 | Direct | |||
| Martha Shadan | CVRX | Common Stock | Award | 8,720 | 8,720 | 01 Jun 2026 | Direct | |||
| Martha Shadan | CVRX | Stock Option (right to buy) | Award | 11,182 | 11,182 | 01 Jun 2026 | Direct | |||
| Michael D. Dale | CVRX | Common Stock | Award | 29,005 | 29,005 | 01 Jun 2026 | Direct | |||
| Michael D. Dale | CVRX | Stock Option (right to buy) | Award | 36,252 | 36,252 | 01 Jun 2026 | Direct | |||
| Philip B. Adamson | CVRX | Common Stock | Sale | -2.01% | $9,973 | $7.90 | -1,262 | 61,578 | 02 Mar 2026 | Direct |
| Gregory Morrison | CVRX | Common Stock | Award | 34,000 | 34,000 | 02 Mar 2026 | Direct | |||
| Gregory Morrison | CVRX | Stock Option (right to buy) | Award | 154,500 | 154,500 | 02 Mar 2026 | Direct | |||
| Kevin Hykes | CVRX | Common Stock | Sale | -2.66% | $61,349 | $7.90 | -7,763 | 284,237 | 02 Mar 2026 | Direct |
| Paul Verrastro | CVRX | Common Stock | Sale | -2.08% | $10,146 | $7.90 | -1,284 | 60,551 | 02 Mar 2026 | Direct |
| Jared Oasheim | CVRX | Common Stock | Sale | -1.77% | $13,781 | $7.90 | -1,744 | 96,703 | 02 Mar 2026 | Direct |
| Robert Allen John | CVRX | Common Stock | Sale | -4.4% | $31,326 | $7.90 | -3,964 | 86,036 | 02 Mar 2026 | Direct |
| Philip B. Adamson | CVRX | Common Stock | Award | 187.7% | 41,000 | 62,840 | 27 Feb 2026 | Direct | ||
| Philip B. Adamson | CVRX | Stock Option (right to buy) | Award | 62,000 | 62,000 | 27 Feb 2026 | Direct | |||
| Kevin Hykes | CVRX | Common Stock | Award | 119.6% | 159,000 | 292,000 | 27 Feb 2026 | Direct | ||
| Kevin Hykes | CVRX | Stock Option (right to buy) | Award | 238,000 | 238,000 | 27 Feb 2026 | Direct | |||
| Paul Verrastro | CVRX | Common Stock | Award | 267.3% | 45,000 | 61,835 | 27 Feb 2026 | Direct | ||
| Paul Verrastro | CVRX | Stock Option (right to buy) | Award | 67,000 | 67,000 | 27 Feb 2026 | Direct | |||
| Jared Oasheim | CVRX | Common Stock | Award | 162.9% | 61,000 | 98,447 | 27 Feb 2026 | Direct | ||
| Jared Oasheim | CVRX | Stock Option (right to buy) | Award | 91,000 | 91,000 | 27 Feb 2026 | Direct | |||
| Robert Allen John | CVRX | Common Stock | Award | 63.6% | 35,000 | 90,000 | 27 Feb 2026 | Direct | ||
| Robert Allen John | CVRX | Stock Option (right to buy) | Award | 52,000 | 52,000 | 27 Feb 2026 | Direct | |||
| Brent Binkowski | CVRX | Common Stock | Award | 90.4% | 15,000 | 31,600 | 27 Feb 2026 | Direct | ||
| Brent Binkowski | CVRX | Stock Option (right to buy) | Award | 23,000 | 23,000 | 27 Feb 2026 | Direct | |||
| Mudit K. Jain | CVRX | Common Stock | Purchase | 5.01% | $297,592 | $6.36 | 46,800 | 980,183 | 20 Feb 2026 | See footnote |
| Mudit K. Jain | CVRX | Common Stock | Purchase | 11.9% | $2,785 | $4.64 | 600 | 5,650 | 18 Feb 2026 | Direct |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.16% | $63,560 | $10.03 | -6,337 | 4,024,861 | 26 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.16% | $63,560 | $10.03 | -6,337 | 4,040,861 | 26 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.4% | $160,480 | $10.03 | -16,000 | 4,031,198 | 25 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.05% | $22,132 | $10.06 | -2,200 | 4,047,198 | 24 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.01% | $5,000 | $10.00 | -500 | 4,049,398 | 21 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.02% | $10,000 | $10.00 | -1,000 | 4,049,898 | 12 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | $2,000 | $10.00 | -200 | 4,050,898 | 07 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. | |
| Johnson & Johnson | CVRX | Common Stock | Sale | -1.28% | $534,310 | $10.21 | -52,332 | 4,051,098 | 06 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Brent Binkowski | CVRX | Common Stock | Award | 16,600 | 16,600 | 11 Aug 2025 | Direct | |||
| Brent Binkowski | CVRX | Stock Option (right to buy) | Award | 74,900 | 74,900 | 11 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.